Journal of Clinical Immunology

, Volume 17, Issue 2, pp 154–159 | Cite as

Modification of in Vivo and in Vitro TNF-α, IL-1, and IL-6 Secretion by Circulating Monocytes During Hyperbaric Oxygen Treatment in Patients with Perianal Crohn's Disease

  • G. Weisz
  • A. Lavy
  • Y. Adir
  • Y. Melamed
  • D. Rubin
  • S. Eidelman
  • S. Pollack


Treatment of perianal inflammatory lesions in Crohn's disease (CD) is unsatisfactory and novel treatment modalities are pursued. We have recently reported a good clinical effect of hyperbaric oxygen (HBO) treatment in perianal CD. In the present study, seven patients with perianal CD were subjected to daily sessions of HBO in a multiplace hyperbaric chamber. Each patient received a total of 20 sessions during a time period of 1 month, and IL-1, IL-6, and TNF-α measurements were done several times during the initial sessions and after completing therapy. Pretreatment cytokine levels were elevated in patients compared to age-matched 10 normal controls. During the first 7 days of treatment, IL-1, IL-6, and TNF-α levels in supernatants of LPS-stimulated monocytes derived from patients' peripheral blood were decreased compared to pretreatment levels. Parallel measurements of serum IL-1 levels revealed an initial elevation and thereafter decreased levels, which remained low throughout the first week of HBO treatment. After completion of therapy, cytokine levels increased to pretreatment values. We conclude that alterations in secretion of IL-1, IL-6, and TNF-α may be related to the good clinical effect of HBO treatment in CD patients with perianal disease.

Crohn's disease hyperbaric oxygen cytokines 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Melamed Y, Shupak A, Bitterman H: Medical problems associated with underwater diving. N Engl J Med 326:30–35, 1992Google Scholar
  2. 2.
    Grim PS, Gottlieb LJ, Boddie A, Batson E: Hyperbaric oxygen therapy. JAMA 263:2216–2220, 1990Google Scholar
  3. 3.
    Lavy A, Weisz G, Adir Y, Ramon Y, Melamed Y, Eidelman S: Hyperbaric oxygen for perianai Crohn's disease. J Clin Gastroenterol 19:202–205, 1994Google Scholar
  4. 4.
    Wakefield AJ, Sawyerr AM, Dhillon AP, Pittilo RM, Rowles PM, Lewis AA, Pounder RE: Pathogenesis of Crohn's disease: Multifocal gastrointestinal infarction. Lancet 2:1057–1062, 1989Google Scholar
  5. 5.
    Thompson H: Histopathology of Crohn's disease. In Inflammatory Bowel Diseases, 2nd ed, RN Allan, MRB Keighley, J Alexander-Williams, CF Hawkins (eds). Edinburgh, Churchill Livingstone, 1990, pp 263–285Google Scholar
  6. 6.
    Reinecker H-C, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A: Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 94:174–181, 1993Google Scholar
  7. 7.
    Matsushima K, Morishita K, Yoshimura T, et al.: Molecular cloning of a human monocyte-derived neutrophil chemotatic factor (MDNCF) and the induction of MDNCF mRNA by interleukin I and tumour necrosis factor. J Exp Med 167:1883–1893, 1988Google Scholar
  8. 8.
    Van Dullemen HM, Van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129–135, 1995Google Scholar
  9. 9.
    Derkx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, Tytgat G, Van Deventer S: Tumor-necrosis-factor antibody treatment in Crohn's disease. Lancet 342:173–174, 1993Google Scholar
  10. 10.
    Brady CE, Cooley BJ, Davis JC: Healing of severe perineal and cutaneous Crohn's disease with hyperbaric oxygen. Gastroenterology 97:756–760, 1989Google Scholar
  11. 11.
    Knighton DR, Halliday B, Hunt TK: Oxygen as an antibiotic. Arch Surg 121:191–202, 1986Google Scholar
  12. 12.
    Hunt TK, Pai MP: The effect of varying ambient oxygen tensions on wound metabolism and collagen synthesis. Surg Gynecol Obstet 135:561–568, 1972Google Scholar
  13. 13.
    La Van FB, Hunt TK: Oxygen and wound healing. Clin Plast Surg 17:463–468, 1990Google Scholar
  14. 14.
    Ginaldi L, Pilotti L, Sacchetti S, Laurenti R, Pizzuto F, Valdarnini D: Modification of immune parameters after hyperbaric oxygen treatment in healthy volunteers. J Hyperbaric Med 6:25–31, 1991Google Scholar
  15. 15.
    Bitterman N, Bitterman H, Kinarty A, Melamed Y, Lahat N: Effect of a single exposure to hyperbaric oxygen on blood mononuclear cells in human subjects. Undersea Biomed Res 20:197–204, 1993Google Scholar
  16. 16.
    Saito K, Tanaka Y, Ota T, Ota S, Yamashita U: Suppressive effect of hyperbaric oxygenation on immune responses of normal and autoimmune mice. Clin Exp Immunol 86:322–327, 1991Google Scholar
  17. 17.
    Inamoto Y, Okuno F, Saito K, Tanaka Y, Watanabe K, Morimoto I, Yamashita U, Eto S: Effect of hyperbaric oxygenation on macrophage function in mice. Biochem Biophys Res Comm 179:886–891, 1991Google Scholar
  18. 18.
    Rister M: Efect of hyperoxia on phagocytosis. Blut 45:157–163, 1982Google Scholar
  19. 19.
    Best WR, Becktel JM, Singleton JW, Kern F: Development of a Crohn's disease activity index. Gastroenterology 70:439–444, 1976Google Scholar
  20. 20.
    Srugo I, Berger A, Lapidot Z, Katz R, Pollack S: Interleukin 1 secretion by blood monocytes of septic premature infants. Infection 19:150–154, 1991Google Scholar
  21. 21.
    Feldmeier JJ, Boswell RN, Brown M, Shaffer P: The effects of hyperbaric oxygen on the immunologic status of healthy human subjects. In Proceedings of the Eighth International Congress on Hyperbaric Medicine, EP Kindwall (ed). San Pedro, CA, Best, 1987, pp 41–46Google Scholar
  22. 22.
    Nyland H, Naess A, Eidsvik S, Glette J, Matre R, Hordnes C: Effect of hyperbaric oxygen treatment on immunological parametres in multiple sclerosis. Acta Neurol Scand 79:306–310, 1989Google Scholar
  23. 23.
    Fischer BH, Marks M, Reich T: Hyperbaric oxygen treatment of multiple sclerosis: A randomized, placebo-controlled, double blind study. N Engl J Med 308:181–186, 1983Google Scholar
  24. 24.
    Geller AS, Cohen A: Arterial inflammatory infiltration in Crohn's disease. Arch Pathol Lab Med 107:473–479, 1983Google Scholar
  25. 25.
    Tanner AR, Arthur MJP, Wright R: Macrophage activation, chronic inflammation and gastrointestinal disease. Gut 25:760–783, 1984Google Scholar
  26. 26.
    Hermanowicz A, Gibson PR, Jewell DP: The role of phagocytes in inflammatory bowel disease. Clin Sci 69:241–249, 1985Google Scholar
  27. 27.
    Thomsen MK, Larsen CG, Thomsen HK, Kirstein D, Skak-Nielsen T, Ahnfelt-Ronne I, Thestrup-Pedersen K: Recombinant human interleukin-8 is a potent activator of canine neutrophil aggregation, migration, and leukotriene B4 biosynthesis. J Invest Dermatol 96:260–266, 1991Google Scholar
  28. 28.
    Lobos EA, Sharon P, Stenson WF: Chemotactic activity in inflammatory bowel disease: Role of leukotriene B4. Dig Dis Sci 32:1380–1388, 1987Google Scholar
  29. 29.
    Nathan CF: Secretory products of macrophages. J Clin Invest 79:319–326, 1987Google Scholar
  30. 30.
    Satsangi J, Walstencroft JC, Cason J, Ainley CC, Dumonde DC, Thompson RPH: Interleukin-1 in Crhon's disease. Clin Exp Immunol 67:594–605, 1987Google Scholar
  31. 31.
    Mitsuyama K, Toyonaga A, Sasaki E, Watanabe K, Tateishi H, Nishiyama T, Saiki T, Ikeda H, Tsuruta O, Tanikawa K: IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease. Clin Exp Immunol 96:432–436, 1994Google Scholar
  32. 32.
    Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA Jr, O'Connor JV: Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 163:1433–1439, 1986Google Scholar

Copyright information

© Plenum Publishing Corporation 1997

Authors and Affiliations

  • G. Weisz
    • 1
  • A. Lavy
    • 2
  • Y. Adir
    • 1
  • Y. Melamed
    • 1
  • D. Rubin
    • 3
  • S. Eidelman
    • 2
  • S. Pollack
    • 3
  1. 1.Rambam Medical Center and the B. Rappaport faculty of Medicine—Technion, Israel Institute of TechnologyIsraeli Naval Hyperbaric InstituteHaifaIsrael
  2. 2.Rambam Medical Center and the B. Rappaport Faculty of Medicine—Technion, Israel Institute of TechnologyGastroenterology InstituteHaifaIsrael
  3. 3.Allergy & AIDS, Rambam Medical Center and the B. Rappaport Faculty of Medicine—Technion, Israel Institute of TechnologyInstitute of ImmunologyHaifaIsrael

Personalised recommendations